Jennifer Pietenpol Archive — Page 5 of 6
-
September 9, 2016
In search of new cancer targets
Vanderbilt researchers developed a new algorithm to find clinically targetable gene rearrangements in cancers. -
May 26, 2016
Precision medicine already changing cancer treatment strategies
The ability to test patients’ cancers for individual differences, mainly at the genetic level, and to make treatment decisions based on those differences is the hallmark of precision medicine, and Vanderbilt University Medical Center (VUMC) is among the leaders of this new approach to diagnosis and treatment. -
April 14, 2016
Pietenpol named Executive Vice President for Research
Jennifer Pietenpol, Ph.D., director of the Vanderbilt-Ingram Cancer Center, B.F. Byrd Jr. Professor of Molecular Oncology and Professor of Biochemistry, Cancer Biology and Otolaryngology, has been named Executive Vice President for Research at Vanderbilt University Medical Center (VUMC). Her appointment is effective May 1. -
April 1, 2016
New role identified for p73 gene
The p73 gene is required for the generation of cilia – hair-like projections on cells – findings that could have implications for the study of lung diseases and sterility. -
March 17, 2016
T.J. Martell Foundation lauds Pietenpol’s research
Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of Vanderbilt-Ingram Cancer Center (VICC), was honored with the Medical Research Advancement Award during the 8th Annual T.J. Martell Foundation Nashville Honors Gala held recently at the Omni Nashville Hotel. -
October 1, 2015
VICC investigators land Komen breast cancer grants
Two Vanderbilt-Ingram Cancer Center (VICC) investigators — Jennifer Pietenpol, Ph.D., B.F. Byrd Jr. Professor of Oncology and director of VICC, and Valerie Jansen, M.D., Ph.D., medical oncology fellow — have received new cancer research grants awarded by Susan G. Komen, the world’s largest nonprofit funder of breast cancer research. -
September 17, 2015
Strong scores put VICC among top NCI centers
Vanderbilt-Ingram Cancer Center (VICC) has been recognized for the impact of its research programs and excellence in patient care by a panel of National Cancer Institute (NCI) reviewers, receiving an overall “exceptional” score as part of the renewal of the Cancer Center Support Grant (CCSG).